Thrombocytosis (Thrombocythemia)

03/01/2001 - "Aspirin is effective for patients with thrombocythemia, but most other cases are very resistant to treatment. "
01/01/2000 - "Low-dose aspirin will prevent the microvascular thrombotic complications of thrombocythemia associated with PV in remission after phlebotomy, but lacks myelosuppressive activity. "
06/01/1986 - "Thrombocytosis was previously present as attested by a blood count one year before (in one case) and by long-term peripheral vasomotor troubles, electively improved by aspirin (in two cases). "
02/01/2015 - "Screening for AvWS is recommended before administrating aspirin, in the presence of extreme thrombocytosis."
06/01/2013 - "Screening for clinically significant AvWS is recommended before administrating aspirin in the presence of extreme thrombocytosis."

10/01/2003 - "These patients received anagrelide for 25 months resulting in a significant improvement of thrombocytosis. "
01/01/1992 - "Our experience suggests that anagrelide should become a useful agent in controlling the thrombocythemia seen in chronic myeloproliferative diseases and can be effective in patients in whom treatment with currently available agents has failed."
01/01/1992 - "To evaluate the safety and efficacy of anagrelide when used to reduce platelet counts in patients with thrombocytosis. "
11/01/2004 - "Herein, we report the results of a long-term study of patients with ET treated with anagrelide to control thrombocytosis. "
10/01/2004 - "In this retrospective multi-centre study, we report our experience with anagrelide in the treatment of thrombocytosis in patients with chronic myeloproliferative diseases. "

01/01/1991 - "Recently, many authors have reported the therapeutical efficacy of interferon (IFN) in MPD with thrombocytosis in decreasing platelet number. "
03/25/1989 - "Thrombocytosis recurred rapidly when treatment was stopped, but a second remission could be achieved by resumption of interferon therapy."
01/01/1987 - "Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. "
09/30/1989 - "In a prospective open study 16 consecutive patients with a myeloproliferative syndrome and thrombocytosis were treated with interferon (IFN) alpha-2a. "
11/13/1993 - "The effect of interferons in the correction of thrombocytosis in chronic myeloproliferative syndromes is well known. "

10/01/1992 - "In comparison, serum IL-6 levels of patients with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; range 0-933; P < 0.001). "
10/01/1991 - "In contrast, serum IL-6 levels of 143 patients (158 samples) with reactive thrombocytosis were significantly greater than controls (38.3 U/ml +/- 94.6; P less than 0.001), with 83% of the samples showing elevated serum IL-6. "
12/01/2006 - "This study showed that thrombocytosis in HSP patients is a type of inflammatory reactive thrombocytosis, and that IL-6 may also play a role in the pathogenesis of HSP."
09/01/2002 - "This study provided no direct evidence as to the mechanism responsible for the elevated platelet count, but mediation by interleukin-6 (IL-6) was concluded to be an attractive hypothesis, consistent with prior studies of IL-6 in reactive thrombocytosis and of IL-6 in ENL."
09/01/2015 - "Advanced OCCC (hazard ratio [HR] 3.38, P<0.0001), thrombocytosis (HR 1.42, P=0.032) and elevated IL-6 (HR 8.90, P=0.046) were independent predictors of VTE. "

04/01/2015 - "An 81-year-old Caucasian woman, affected by polycytemia vera lasting 17 years, presented in March 2012 with hyperleukocytosis, absolute neutrophilia, and thrombocytosis despite hydroxyurea treatment. "
05/01/2014 - "Cyclical thrombocytosis was documented in 29 patients (15%), the majority of whom were receiving hydroxyurea. "
01/01/2014 - "Hydroxyurea is an antineoplastic agent commonly used to treat essential thrombocytosis. "
01/01/2013 - "A detailed investigation revealed an essential thrombocytosis necessitating treatment with hydroxyurea and indefinite dual antiplatelet therapy."
01/01/2012 - "Longitudinal melanonychia in a patient with essential thrombocytosis under treatment with hydroxyurea."

04/01/1995 - "The aims of the study were verify the ability of quantitation of serum C-reactive protein in the differential diagnosis of primary thrombocytosis. "
04/01/2013 - "Abnormal laboratory findings such as low albumin, raised erythrocyte sedimentation rate, anaemia, thrombocytosis and high C-reactive protein were found in nearly half of the patients. "
03/01/2013 - "All patients developed a raised C-reactive protein, whereas most developed acute liver injury, neutrophilia, and thrombocytosis. "
09/01/2012 - "In MIBC, serum C-reactive protein and thrombocytosis have been recently incorporated into basic prognostic models and demonstrated an increase in the predictive accuracy of standard pathological risk factors. "
05/01/2012 - "The associations between reactive thrombocytosis and C-reactive protein, the coagulation profile and Sequential Organ Failure Assessment score were also evaluated. "

02/01/2002 - "These results indicate that plasma thrombopoietin levels may be helpful in distinguishing between clonal and reactive thrombocytosis."
05/01/1998 - "Thrombopoietin levels may be helpful in distinguishing between clonal thrombocytosis and reactive thrombocytosis. "
09/01/2004 - "The aims of this study were to evaluate the prevalence and clinical significance of thrombocytosis in HCC patients and its relationships with serum thrombopoietin (TPO). "
02/01/2002 - "The aim of this study is to assess circulating thrombopoietin concentrations in patients with both clonal and reactive thrombocytosis (RT), which are two distinct categories of extreme platelet production circumstances. "
12/01/1996 - "These results confirm the findings of two previous studies that thrombopoietin expression is not the main cause of thrombocytosis in the 3q21q26 syndrome."

01/01/1999 - "Although it is possible that spontaneous remission (frequency 5%-10%) of chronic ITP coincided with the femoral lengthening, limb lengthening could also have caused the thrombocytosis. "
01/01/1991 - "A morphometric and immunohistochemical study was performed on trephine biopsies of the bone marrow in patients showing idiopathic thrombocytopenic purpura (ITP) and reactive thrombocytosis (RTH). "
10/01/2013 - "We performed thrombocytapheresis in a young lady with chronic idiopathic thrombocytopenic purpura (ITP) who developed postsplenectomy reactive thrombocytosis. "
08/01/1981 - "The urinary extract from patients with severe, chronic idiopathic thrombocytopenic purpura (ITP) was capable of inducing significant thrombocytosis in rats in vivo and enhancing megakaryocyte colony formation in culture of mouse bone marrow cells. "
06/01/1995 - "Bone marrow studies are not necessary in children who have reactive lymphocytes; in most children who have leukopenia, leukocytosis, or thrombocytosis; and in many who have ITP. "

09/01/2011 - "In preliminary findings of a Phase III trial in patients with primary, postpolycythemia-vera, or postessential-thrombocythemia myelofibrosis, administration at an initial dosage of 15 or 20 mg twice daily led to a spleen-volume response rate (≥ 35% reduction at 24 weeks) of 41.9 versus 0.7% for placebo (p < 0.0001); furthermore, 45.9% of the ruxolitinib recipients had ≥ 50% improvement in symptom score (on the modified Myelofibrosis Symptom Assessment Form version 2.0) versus 5.3% for placebo (p < 0.0001). "
09/16/2010 - "We conducted a phase 1−2 trial of INCB018424 in patients with JAK2 V617F−positive or JAK2 V617F−negative primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–polycythemia vera myelofibrosis. "
09/01/2015 - "Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms."
06/15/2012 - "Food and Drug Administration (FDA) granted full approval to ruxolitinib, (Jakafi; Incyte Corp.), an inhibitor of the Janus kinases 1 and 2, for the treatment of patients with intermediate- or high-risk myelofibrosis, including primary myelofibrosis, postpolycythemia vera myelofibrosis, and postessential thrombocythemia myelofibrosis. "

01/07/1996 - "Since extreme thrombocytosis developed, the treatment was continued with interferon alpha. "
01/01/1993 - "[Alpha interferon treatment of chronic myeloproliferative disease associated thrombocytosis]."
01/01/1991 - "The selective thrombocytosis-reducing effect of alpha interferon was maintained for long periods of time in most patients without serious side effects. "
02/01/1994 - "Interferon-alpha (IFN-alpha) treatment has been shown to be highly effective in inhibiting human megakaryocytopoiesis and controlling thrombocytosis in patients with myeloproliferative disorders. "
01/01/1990 - "Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis."

12/01/2014 - "The two patients with splenectomy and resection of ⅔ of the spleen developed a transient thrombocytosis indicating impaired clearance of the spleen. "
06/01/2012 - "In this study, we evaluated reactive thrombocytosis that developed after splenectomy with or without additional organ resection. "
01/01/1957 - "[Clinical and biological study of a prolonged thrombocythemia after splenectomy]."
12/01/2015 - "Splenectomy increases the risk for VTE, however reactive thrombocytosis is not associated with this higher incidence. "
12/01/2015 - "Thrombocytosis following splenectomy is a common occurrence. "

05/01/2009 - "Thrombocytosis also occurred after post remission chemotherapies, although the degree of thrombocytosis gradually decreased. "
01/01/2012 - "In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 10(9)/l (range 457-1,385). "
01/01/2007 - "The temporal relationship between thrombocytosis at the time of chemotherapy administration and the clinical onset of thrombotic events suggests that thrombocytosis plays a role in triggering thrombotic complications."
03/01/2005 - "Thrombocytosis occurred in 45% patients before treatment, and in none when the 6th course of chemotherapy was given. "
08/15/1993 - "Combined plateletpheresis and chemotherapy is a rapidly effective initial treatment for patients with MPD with symptomatic thrombocytosis. "

10/01/2006 - "Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation."
07/01/2003 - "We describe the course of 25 patients with myelofibrosis (MF) due to agnogenic myeloid metaplasia (n=19) or essential thrombocytosis (n=6) who underwent allogeneic stem cell transplantation (SCT) at one of two Canadian centers. "
01/15/2015 - "RPs are a promising laboratory tool for evaluation of idiopathic thrombocytopenia (differentiating hypoproduction from accelerated platelet destruction), chemotherapy and after stem cell transplantation (predicting platelet recovery) and thrombocytosis (estimating platelet turnover). "
03/01/2013 - "Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation."
12/17/2009 - "From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70). "

10/01/2004 - "At 3-7 days after treatment, subjects presented also with a mild tendency towards a normocytic anaemic state (p < 0.01) and a degree of lympho-thrombocytosis (p < 0.05). "
04/01/2003 - "60% cases had thrombocytosis at diagnosis in comparison to 2.3% after treatment. "
01/01/2013 - "In conclusion, it is important to make an evaluation for myeloproliferative diseases in clear "sugar" cell tumor in adults if thrombocytosis was lasting after treatment."
05/01/2009 - "These findings suggest that in APL patients, thrombocytosis after treatment with ATRA and or chemotherapy may be caused by increased plasma levels of both of IL-6 and TPO."
09/01/2004 - "After treatment with iron, the patient underwent splenectomy which resulted in almost immediate rise of the number of all blood cells, and even thrombocytosis. "

01/01/1994 - "In the patient with essential thrombocytosis, hepatic transplantation only relieved the symptoms of the predisposing thrombogenic condition; it did not cure the underlying disorder. "
11/01/2007 - "The prevalence, natural history, and implications of reactive thrombocytosis after liver transplantation (LT) are unknown. "
01/01/2004 - "Except for patients with underlying myeloproliferative diseases (MPD), thrombocytosis is rarely encountered in cirrhotic patients after liver transplantation. "
02/01/2003 - "Essential thrombocytosis and liver transplantation."
01/01/2004 - "We present two patients with extreme reactive thrombocytosis (over 1,000 x 10(9)/l) due to intra-abdominal sepsis after liver transplantation. "